The Oncology Brothers, Dr. Wallis Give Their Thoughts on PROpel, TALAPRO-2, and EV-103 Cohort K

By Oncology Brothers, Christopher Wallis, MD, PhD, FRCSC - Last Updated: June 5, 2023

The Oncology Brothers—Rahul Gosain, MD, Wilmot Cancer Institute at Webster, and Rohit Gosain, MD, UPMC Hillman Cancer Center—chat with Christopher Wallis, MD, PhD, University of Toronto, on the ASCO research presented in PARP inhibitors for GU cancers, as well as neoadjuvant immunotherapy and enfortumab vedotin for bladder cancer.

View more ASCO 2023 videos.

Advertisement
Advertisement